ライフサイエンスコーパス: PRA

1 PRA and PRB have distinct roles in gene expression and i

2 PRA in the Lhasa Apso (LA) dog has not previously been c

3 PRA is normally synthesized by phosphoribosyl pyrophosph

4 PRA is safe, avoids intra-abdominal adjacent organ mobil

5 PRA may be the preferred technique for removing benign a

6 PRA of 25.15 ng/mL at day 3 had sensitivity and specific

7 PRA of 25.15 ng/mL at day 3 had sensitivity and specific

8 PRA represses the PRB activity.

9 PRA screening is used to determine the presence of pre-f

10 PRA was equivalent between nonresponders and responders

11 A total of 135 PRA, 126 primary anastomoses with defunctioning stoma (P

12 R,1.21 [95% CI,1.12 to 1.31]) in PRA 1%-19%, PRA 20%-79%, and PRA 80%-100% categories compared with P

13 xty-five patients were included, of whom 61 (PRA 30, LTLA 31) completed the 5-year follow-up.

14 Twelve percent of the cohort was PRT-75+/PRA-, and only 5% of the patients were PRA+/PRT-75+, ind

15 A PRA value of >/=10% was used to define clinically meanin

16 ional data), with 9 (7.4%) patients having a PRA more than 90%.

17 e use of GWAS and subsequent sequencing of a PRA case, we have identified a LINE-1 insertion in the r

18 reas only one of seven (14%) patients with a PRA greater than 15% had AR.

19 0.27 L; P = 0.72) and plasma renin activity (PRA) (20.5 +/- 7.03 vs. 23.2 +/- 8.24 ng/mL/hour; P = 0.

20 Ly markedly raised plasma renin activity (PRA) and aldosterone, and exerted more effective anti-al

21 uced water intake and plasma renin activity (PRA) and found that weight loss decreased water intake a

22 hod was developed for plasma renin activity (PRA) and was evaluated on fifty-three clinical samples.

23 longed suppression of plasma renin activity (PRA) is observed after aliskiren withdrawal.

24 t sensitivity and low plasma renin activity (PRA).

25 serum aldosterone and plasma renin activity (PRA).

26 lization according to plasma renin activity (PRA).

27 Plasma renin activity (PRA; >4 ng/mL/hour) was used as a surrogate of effective

28 0.27 L; P = 0.72) and plasma renin activity (PRA; 20.5 +/- 7.03 versus 23.2 +/- 8.24 ng/mL/hour; P =

29 roxyl radical; (b) peroxyl radical addition (PRA) to a "C=C" double bond.

30 osterior retroperitoneoscopic adrenalectomy (PRA) is a minimally invasive approach to removal of the

31 rategy only when risk of complications after PRA and PADS reached 50% and 44%, respectively.

32 Complications after PRA reduced patients QALYs to a baseline of 2.713.

33 ith 9.44 QALYs after HP and 9.02 QALYs after PRA.

34 ifference with IRD transplantation were age, PRA, previous transplant, and the expected time until th

35 All PRA procedures were performed using a 3-trocar technique

36 Phosphoribosyl amine (PRA) is an intermediate in purine biosynthesis and also

37 Phosphoribosyl amine (PRA) is the first intermediate in the common portion of

38 rst common metabolite, phosphoribosyl amine (PRA), can be generated in the absence of the first enzym

39 d States by PCR restriction enzyme analysis (PRA) of the 441-bp Telenti fragment of the hsp-65 gene a

40 ad the same PCR restriction enzyme analysis (PRA) profile as the hsp65 gene of M. porcinum (ATCC 3377

41 Pest risk analysis (PRA) is key to prioritize agricultural biosecurity effor

42 this process "pattern recognition analysis" (PRA).

43 12 to 1.31]) in PRA 1%-19%, PRA 20%-79%, and PRA 80%-100% categories compared with PRA 0%, respective

44 essure reduction and blunted aldosterone and PRA responses to the DASH diet.

45 ve (P < .0001) and AMR patients with DSA and PRA > 10% were identified as the subgroup with significa

46 n age, end-stage renal disease etiology, and PRA matched group of patients remaining on dialysis duri

47 A periodontal examination and PRA were performed after active periodontal therapy and

48 LiAlH(4), to completely reduce both HAT and PRA-derived products and the relative quantitation of to

49 8.3, 95% CI 2.5-27.9), followed by HCV+ and PRA > 20%.

50 erforated diverticulitis lies between HP and PRA.

51 less than 20%, group 2: 16 retransplants and PRA more than 20% who were FC crossmatch-negative, and g

52 -negative, and group 3: 20 retransplants and PRA more than 20% who were FC crossmatch-positive.

53 addition, endpoint titers, MESF units, and % PRA of 26 sera were established.

54 on (AVR) than panel reactive HLA antibodies (PRA).

55 aphics, cytotoxic panel reactive antibodies (PRA) against T-cell targets and flow cytometric crossmat

56 detected by FLOW panel reactive antibodies (PRA) and donor-specific cellular sensitization was detec

57 ree of anti-human panel reactive antibodies (PRA) and xenoreactivity against either standard or GalT-

58 of pretransplant panel reactive antibodies (PRA) are known to be associated with detrimental effects

59 Panel reactive antibodies (PRA) were determined using Flowbeads and concentration c

60 her percentage of panel-reactive antibodies (PRA), were more likely to receive a cadaveric transplant

61 the assessment of panel reactive antibodies (PRA).

62 didates with high panel-reactive antibodies (PRA).

63 nd had lower peak panel-reactive antibodies (PRA; 5.1% vs. 15.6%, P=0.07) when compared with their bi

64 transplants, high panel reactive antibodies (PRAs) (>20%), and prolonged cold ischemic times (>24 hou

65 dies, measured as panel reactive antibodies (PRAs), are related to mortality in ESRD.

66 sitized patients (panel reactive antibodies [PRA] <20%) receiving a primary transplant in 1999 or lat

67 rval [CI] 1.1-7.9), panel reactive antibody (PRA) > 20% (HR 2.8, 95% CI 1.1-7.2) and female donor gen

68 Panel reactive antibody (PRA) analysis was performed on posttransplant sera (2 we

69 Cytotoxic panel-reactive antibody (PRA) and SAB assays were analyzed in HTX recipients unde

70 patients with a low panel reactive antibody (PRA) before transplantation and follow-up PRA testing at

71 tcome was change in panel reactive antibody (PRA) from prior to recipient's initial transplant to the

72 ry transplants with panel-reactive antibody (PRA) less than 20%, group 2: 16 retransplants and PRA mo

73 ed sensitization as panel reactive antibody (PRA) more than 10% or a positive T-cell crossmatch (TXM)

74 re in-patients with panel reactive antibody (PRA) more than or equal to 80%.

75 four an increase in panel reactive antibody (PRA) of at least 20% (P=0.002).

76 The Class I HLA panel reactive antibody (PRA) only significantly increased in adults.

77 ed by FLXM and flow panel reactive antibody (PRA) screening beads.

78 Pretransplantation panel reactive antibody (PRA) testing assesses posttransplantation risk for antib

79 Panel-reactive antibody (PRA) testing provides assessment of the breadth of sensi

80 ansplant and having panel reactive antibody (PRA) values greater than 85% and 50 randomly selected no

81 Mean peak panel-reactive antibody (PRA) was 47+/-32.

82 s (Ab), reported as panel-reactive antibody (PRA), prolong patient waiting time for kidney transplant

83 of 35 pretransplant panel reactive antibody (PRA)-negative patients with failed allografts were exami

84 unction of race and panel reactive antibody (PRA).

85 HLA, and recipient panel-reactive antibody (PRA).

86 odies or to percent panel-reactive antibody (PRA; by complement-dependent cytotoxicity) and anti-MICA

87 tion of percentage panel reactive antibody ("PRA screen") with limited antibody identification testin

88 ed to HLA antigens (panel reactive antibody [PRA] > or =50% monthly for 3 mo) enrolled onto an NIH-sp

89 highly sensitized (panel reactive antibody [PRA] of 52%) recipient.

90 sensitized patient (panel reactive antibody [PRA]>80%; HS).

91 ysis patients who differ from those that are PRA+.

92 Because PRB, as well as PRA, coimmunoprecipitated with FAK, both isoforms can in

93 ociation of the periodontal risk assessment (PRA) model with the recurrence of periodontitis and toot

94 e performed a probabilistic risk assessment (PRA) of the donor-recipient matching processes for thora

95 of early-onset progressive retinal atrophy (PRA) was supported by reduced direct and consensual pupi

96 somal recessive progressive retinal atrophy (PRA) with a late onset at 3-6 years of age or older.

97 cessive form of progressive retinal atrophy (PRA), is phenotypically similar to early-onset forms of

98 photographs based on the pupil ruff atrophy (PRA) grading system.

99 Among 2484 CLK recipients with available PRA or TXM information, 30% had positive TXM or PRA more

100 f AKI in this setting are prerenal azotemia (PRA), acute tubular necrosis (ATN), and hepatorenal synd

101 lative contributions of PR isoforms A and B (PRA and PRB, respectively) in cancer cell migration rema

102 Baseline PRA levels were similar in both groups.

103 However, adjustment for baseline PRA attenuated the association between black race and di

104 Associations between PRA and the study outcomes were accentuated in competing

105 ing parental T47-Dco cells that express both PRA and PRB and clonal derivatives that express either P

106 Specific binding of both PRA and PRB to the BCRP promoter through the identified

107 By PRA, 5 isolates had an IC(50) >400 microM and genotypic

108 By PRA, 78 of 81 clinical isolates (96%) from the United St

109 The evolution of calculated PRA (cPRA) reflects the commitment of the transplant com

110 tion rates according to recipient calculated PRAs; however, RATG was associated with an increased ris

111 etinal disease; however, until now no canine PRAs have been associated with this gene.

112 nt cytotoxicity panel reactive antibody [CDC PRA+], C1q+) heart transplant candidates were treated wi

113 a sixfold greater chance of having a T-cell PRA >10% at the time of transplant (p < 0.05), and a fou

114 Sixteen of 18 isolates had concordant PRA and DHA phenotypes.

115 %) group (n = 15) was compared to a control (PRA < 20%) group (n = 27) to evaluate the efficacy of VX

116 ation after LVAD is common despite cytotoxic PRA being negative.

117 TrpD-dependent PRA formation in vitro was inhibited by S. enterica YjgF

118 ession was discontinued invariably developed PRA+.

119 Thirteen subjects displayed PRA+ at follow-up, eight of whom were de novo.

120 Sixty-eight PRAs were performed in 62 patients; there were 6 convers

121 B and clonal derivatives that express either PRA (YA cells) or PRB (YB cells) or lack PR (Y cells).

122 so correlated well with a conventional ELISA PRA assay, with a coefficient of determination of 0.98.

123 DA-MB-231 breast cancer cell line expressing PRA and/or PRB, we analyzed the effect of conditional PR

124 f a recessively inherited early-onset feline PRA.

125 Flow PRA determined HLA antibody, donor-specific flow cytomet

126 including 2 patients who expressed>80% Flow PRA.

127 2 months and annually thereafter) using Flow-PRA.

128 morbidity and mortality was 55% and 30% for PRA, 40% and 25% for PADS, and 35% and 20% for HP, respe

129 When adjusted for PRA >20%, HLA mismatch > or =5, and multiple transplant

130 AHR but lost significance when adjusted for PRA >20%.

131 TrpE proteins, was shown to be essential for PRA formation in strains lacking both yjgF and purF.

132 urified with AphA and was also necessary for PRA formation.

133 Patients positive for PRA and sCD30 tests were at significantly higher risk fo

134 erone receptor (PR) negative or positive for PRA, PRB, or both.

135 Quantitative estimates from PRA can be used to assess risks in healthcare and to gau

136 of M. porcinum presently requires hsp65 gene PRA or 16S rRNA or hsp65 gene sequencing.

137 striction analysis targeting the hsp65 gene (PRA-hsp65) and sequencing of the rpoB gene, and suscepti

138 owed that the mutant AS was able to generate PRA from ammonia and phosphoribosyl pyrophosphate.

139 midotransferase mechanisms exist to generate PRA sufficient for thiamine but not purine synthesis.

140 The activity generating PRA in a yjgF mutant background has features that distin

141 llograft loss included HCV, cadaveric graft, PRA >20%, HLA mismatch > or =5, retransplantation, DGF,

142 r incomplete conditioning; the other two had PRA greater than 20%.

143 Here, PRA synthesis was reconstituted in vitro with anthranila

144 resented with BK infection/CMV disease, high PRA greater than 80% seemed to be protective.

145 American race, also contributed to a higher PRA at relisting.

146 kg +/- 7.9 mg/kg, had a significantly higher PRA, and received more plasmapheresis and IVIG at the ti

147 antation prior to kidney transplants, higher PRA, and to receive cadaveric transplants.

148 dults showed significantly increased Class I PRA following VAD support.

149 tients were highly sensitized (class I or II PRA >/=80%).

150 to the manual method and an automated iMALDI PRA assay, but was 4-times faster than the manual approa

151 Of importance, PRA coexpression potentiated PRB-mediated migration, whe

152 uantifying pseudoabsences to enable improved PRA and species distribution modelling.

153 t rejection rate increased after month 12 in PRA+MICA- group and was higher early after transplantati

154 1.18]; and HR,1.21 [95% CI,1.12 to 1.31]) in PRA 1%-19%, PRA 20%-79%, and PRA 80%-100% categories com

155 There was no appreciable change in PRA for patients receiving a first 0 HLA-A, -B, -DR, or

156 transplant were associated with a change in PRA from first to second transplant.

157 Absolute change in PRA levels were examined in general linear models and th

158 subjects, there was no appreciable change in PRA.

159 rapy induces immunogenic tumor cell death in PRA-overexpressing tumors, eliciting an adaptive immune

160 other seven patients, one had a decrease in PRA from 87% to 51% with a concurrent decrease in fluore

161 ; and one patient had a fourfold decrease in PRA titer from 1:64 to 1:16 at 6 months after treatment.

162 =0.042) mostly due to pronounced decrease in PRA+MICA+ group early after transplantation.

163 ever, there was no statistical difference in PRA values among these sera (95%-100%).

164 are significant racial/ethnic differences in PRA among adults awaiting HT is poorly characterized.

165 tus, but at 3 months rejection was higher in PRA+MICA+ versus PRA-MICA- patients (14% vs. 2%; P=0.009

166 ariwise, there was a significant increase in PRA by increasing HLA mismatch of the first transplant.

167 For the primary endpoint of increase in PRA greater than or equal to 20%, African Americans (AA)

168 scriptional activity of the BCRP promoter in PRA-transfected cells; however, cotransfection of PRA an

169 ntracellular localization of Cx43 protein in PRA versus PRB expressing myocytes.

170 arisons, rejection incidence was superior in PRA+MICA- versus PRA-MICA- patients (17% vs. 7%; P=0.007

171 nd was higher early after transplantation in PRA+MICA+ group (P=0.033).

172 quent in patients with ascites and increased PRA than patients without ascites or with ascites but no

173 ASH diet lowers blood pressure and increases PRA and aldosterone concentrations.

174 ull mutation in yjgF allows PurF-independent PRA formation by an unknown mechanism.

175 duct singly responsible for PurF-independent PRA formation.

176 However, PurF-independent PRA synthesis has been observed in strains having differ

177 n of the progesterone receptor (PR) isoforms PRA and PRB resulted in a similarly increased expression

178 Two functional PR isoforms, PRA and PRB, are expressed in progestin-responsive cells

179 terone receptor (PR) exists in two isoforms, PRA and PRB, and both contain activation functions AF-1

180 usly reported canine retinal mutations in LA PRA-affected dogs, we sought to identify the genetic cau

181 on immunosuppressive therapy to 68% by late PRA after weaning (P<0.001).

182 By late PRA testing, 56% of patients were highly sensitized (cla

183 esting at 6 to 24 months after failure (late PRA).

184 yte cell surface markers and HLA Ab levels (%PRA and titers) were tested using flow cytometry.

185 tients did not differ from patients with low PRA transplanted during the same period.

186 ed with an increased risk of BK virus in low-PRA patients.

187 t 6 months after transplantation and maximum PRA but not with the randomization group.

188 Six patients with a mean PRA of 72+/-22% were included in a four-level (L) protoc

189 that distinguish it from the TrpDE-mediated PRA formation shown previously for this enzyme in strain

190 Mostly, PRA remained negative under adequate immunosuppression.

191 Among negative PRA patients risk for AR was significantly elevated if t

192 osyl anthranilate can result in nonenzymatic PRA formation sufficient for thiamine synthesis.

193 s without ascites or with ascites but normal PRA.

194 Moreover, unliganded PRB but not PRA enhanced FAK Tyr397 phosphorylation and colocalized

195 Surprisingly, unliganded PRB but not PRA strongly enhanced cell migration as compared with PR

196 CRP expression in BeWo cells via PRB but not PRA.

197 dysfunction occurred also in the absence of PRA+.

198 We performed a retrospective analysis of PRA status in 66 patients with type 1 diabetes mellitus

199 A negative association of PRA+ with allogeneic solid organ graft survival has been

200 , we sought to identify the genetic cause of PRA in this breed.

201 s available to measure the rate constants of PRA reactions (k(add)).

202 ransfected cells; however, cotransfection of PRA and PRB significantly decreased the progesterone-res

203 We report the largest experience to date of PRA in the United States.

204 ection and enhance the deleterious effect of PRA+ status early after transplantation.

205 ng the widely reported deleterious effect of PRA+ status, but at 3 months rejection was higher in PRA

206 ulted in a similarly increased expression of PRA and PRB, respectively.

207 wing differences were identified in favor of PRA vs LTLA: shorter duration of surgery (50.8 vs 77.3 m

208 e development of a DNA test for this form of PRA in the breed, here termed PRA4 to distinguish it fro

209 gene IMPG2 that is associated with a form of PRA in the LA dog.

210 id producing dogs affected with this form of PRA.

211 d PRA4 to distinguish it from other forms of PRA described in other breeds.

212 hat express an equivalent or higher level of PRA than PRB.

213 retic peptide; P=0.002), and lower levels of PRA (P<0.0001) in black patients.

214 ion was relatively constant across levels of PRA in black patients.

215 nonblack patients with increasing levels of PRA, while the risk of rehospitalization was relatively

216 Monitoring of PRA under immunosuppression may have little clinical val

217 However, outcomes of PRA operations were superior to LTLA in terms of shorter

218 ly challenged by an increasing popularity of PRA, which is believed by many surgeons (not evidence-ba

219 RA-affected LA and three LA without signs of PRA did not identify any exonic or splice site variants,

220 ct was associated with strong stimulation of PRA and aldosterone.

221 his work describes the in vitro synthesis of PRA in the presence of the purified components of the AS

222 ptophan, can play a role in the synthesis of PRA.

223 paper we continued to build on the theme of PRA as a potential resource in retrosynthetic blueprints

224 was coupled to R5020-dependent turnovers of PRA and PRB.

225 It is likely that the future value of PRA will be associated with its utility in leading the w

226 water intake after Iso, but had no effect on PRA.

227 we have identified a new form of early-onset PRA (EOPRA) in the same breed.

228 or TXM information, 30% had positive TXM or PRA more than 10%.

229 her rate of incident hypertension than other PRA phenotypes (incidence rates per 1000 person-years of

230 Overall, PRA+ did not correlate with islet graft outcome: long-te

231 I trial of RTX in chronic dialysis patients (PRA >50%).

232 anuary 2013 to October 2016, 90 HS patients (PRA > 80%, DSA+ = 50 versus DSA- = 40) received kidney t

233 ts, of which 15 (12.3%) sensitized patients (PRA>or=80%) received transplants (P=0.004 compared with

234 Compared to recipients with 0% peak PRA level, recipients with peak PRA levels greater than

235 HR, 0.47; 95% CI, 0.24-0.91; P = 0.02), peak PRA greater than 80% (HR, 0.48; 95% CI, 0.27-0.84; P = 0

236 2.50; 95% CI, 1.02-6.13; P = 0.04), and peak PRA greater than 80% (HR, 0.45; 95% CI, 0.23-0.86; P = 0

237 Blacks had a higher peak PRA than did all other groups and were more likely to be

238 dney transplant recipients with varying peak PRA levels.

239 tized kidney transplant recipients with peak PRA greater than 80% had a greater risk of rejection, gr

240 with 0% peak PRA level, recipients with peak PRA levels greater than 80% were at increased risk of ac

241 (4.5%), and 318 (4.5%) recipients with peak PRA levels of 0%, 1% to 50%, 51% to 80%, and greater tha

242 erved in the presence of basal or persistent PRA+ and graft dysfunction occurred also in the absence

243 Phosphoribosylamine (PRA) is the first intermediate in the common pathway to

244 the thiamine precursor phosphoribosylamine (PRA) by a TrpD-dependent mechanism that is not present i

245 oncentrations, in the context of physiologic PRA phenotypes (suppressed, </=0.50 microg/L per hour; i

246 In contrast, a positive PRA was significantly associated with female gender but

247 patients (donor-specific antibody positive, PRA>80%) were desensitized using IVIG and rituximab.

248 Such an effect of PRB/PRA expression on FAK signaling might thus affect adhesi

249 ity (E/e' ratio), cardiopulmonary pressures, PRA, and natriuretic peptide levels.

250 Pretransplant PRA+ was observed in 10 subjects in the old trials and a

251 s, but the association between pretransplant PRA levels and long-term patient outcomes is unclear.

252 transplant regardless of their pretransplant PRA.

253 contractility acting through its receptors (PRA/B).

254 d ABO and HLA types of donor and recipient, %PRA and specificity of recipient alloantibody, donor/rec

255 pothesized that rituximab (RTX) could reduce PRA via B-cell depletion.

256 However, IVIG significantly reduced PRA levels in study subjects compared with placebo.

257 Mean (+/-SEM) PRA was significantly higher in participants in the DASH

258 A sensitized (PRA >/= 20%) group (n = 15) was compared to a control (P

259 d graft survival, albeit only in sensitized (PRA>5%) patients (hazard ratio 3.98, P=0.014).

260 t failure preserves nonsensitization status (PRA 0%) better than early immunosuppression withdrawal.

261 Thus in P4 stimulated PRA cells Cx43 protein forms GJs, whereas in PRB cells t

262 tains important information that can support PRA.

263 Aliskiren suppresses PRA when given either as monotherapy or in combination w

264 li and Salmonella enterica) that synthesizes PRA from ribose 5-phosphate and glutamine/asparagine.

265 The panel reactive antibody test (PRA) is an established method for assessing posttranspla

266 niation occurring more often after LTLA than PRA (16.1% vs 0%, P=0.022) and need for hernia repair (1

267 We propose that PRA is a master regulator of Cx43 expression, GJ formati

268 Our findings suggest that PRA is an independent predictor of mortality in wait-lis

269 ls and 3-7-fold in YB cells, suggesting that PRA inhibits PRB-dependent induction of VEGF.

270 The PRA model can be useful in particularizing the risk of p

271 The PRA model indicates that changes that followed the March

272 The PRA model indicates that the likelihood of such an event

273 riants that segregated concordantly with the PRA phenotype.

274 a from 115 patients were evaluated for their PRA and sCD30 concentrations.

275 Four of six candidates improved their PRAs (from a mean of 66.2% to 25.5%; P=0.01) and were su

276 The identification of this PRA-associated variant has enabled the development of a

277 ysis of whole-exome sequencing data of three PRA-affected LA and three LA without signs of PRA did no

278 Thus, PRA and PRB differentially regulate BCRP expression in B

279 pothesis that multiple enzymes contribute to PRA synthesis, possibly as the result of side products f

280 Participants were assigned randomly to PRA or LTLA and followed for 5 years after surgery.

281 s used to capture all patients who underwent PRA between October 2005 and February 2008.

282 In contrast, unliganded PRA paradoxically activates Cx43 transcription by intera

283 y (PRA) before transplantation and follow-up PRA testing at 6 to 24 months after failure (late PRA).

284 Relationships between time-varying PRAs and all-cause or cardiovascular mortality were asse

285 ths rejection was higher in PRA+MICA+ versus PRA-MICA- patients (14% vs. 2%; P=0.009).

286 n incidence was superior in PRA+MICA- versus PRA-MICA- patients (17% vs. 7%; P=0.007) at 24 months, c

287 We found that P4, via PRA/B, differentially regulates Cx43 translation to gene

288 t of patients were PRT-75+, whereas 32% were PRA+.

289 T-75+/PRA-, and only 5% of the patients were PRA+/PRT-75+, indicating that T cell alloreactivity did

290 potentiated PRB-mediated migration, whereas PRA alone was ineffective.

291 The mechanisms by which PRA confers an incremental mortality risk in sensitized

292 ients were diagnosed with ATN, 19 (26%) with PRA, and 16 (22%) with HRS.

293 Loss of graft function was associated with PRA+ after lowering of immunosuppression or after infect

294 %, and PRA 80%-100% categories compared with PRA 0%, respectively.

295 baseline within 48 hours were diagnosed with PRA.

296 lant and no patients after LVAD implant with PRA more than 10%.

297 ated with improved survival in patients with PRA greater than 50% (HR, 0.57; 95% CI, 0.34-0.97) and c

298 andomly selected nonsensitized patients with PRA values less than 3%.

299 n pediatric heart transplant recipients with PRA greater than 50% or congenital heart disease, induct

300 0.10%, but did not differ between those with PRA, 0.27%, or ATN, 0.31%, P = 0.54.